Evidence map›Paper›PMID 42463643›Full record

ArticleSignal transduction and targeted therapy2026

A cell-based kinetic framework enables TCR specificity prediction.

Martin Culka, Jonathan Desponds, Jeanne Cheung, Mayra Cruz Tleugabulova, Shirley Ng Palace, Martine Darwish, Roman A Smirnov, Evgeniy Tabatsky, Geraldine Strasser, Andrey S Shaw and 3 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Martin CulkaDepartment of Systems Biology, Columbia University, New York, NY, USA.
Jonathan DespondsGenentech, South San Francisco, CA, USA.
Jeanne CheungGenentech, South San Francisco, CA, USA.
Mayra Cruz TleugabulovaGenentech, South San Francisco, CA, USA.
Shirley Ng PalaceGenentech, South San Francisco, CA, USA.
Martine DarwishGenentech, South San Francisco, CA, USA.
Roman A SmirnovDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Evgeniy TabatskyCouloir Bio Inc., Los Altos, CA, USA.
Geraldine StrasserGenentech, South San Francisco, CA, USA.
Andrey S ShawGenentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5685-0272
Ira MellmanGenentech, South San Francisco, CA, USA.
Andrei ChernyshevVoevodsky Institute of Chemical Kinetics and Combustion SB RAS, Novosibirsk, Russia.
Darya OrlovaGenentech, South San Francisco, CA, USA. dyorlova@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability to predict T-cell receptor (TCR) specificity from sequences could transform immunotherapy, vaccine development, and our understanding of immune recognition. However, progress has been shaped by "edge cases", in which specificity appears to be captured by simplified descriptors, such as sequence motifs or correlations between binding affinity and functional activation. Although informative, these regimes are not representative of the general mode of TCR recognition. Emphasizing such cases has contributed to a drift in the field, where both experimental assay design and computational modeling increasingly rely on nonrepresentative signals, limiting generalizability across antigens and TCRs. We argue that this drift stems from a lack of a clear biophysical definition of TCR specificity and continued reliance on equilibrium binding assays that are not well suited to capture it. These limitations propagate into training datasets, constraining the performance and generalizability of predictive models. To address them, we introduce three key elements. First, we develop a cell-based assay for quantitative measurement of TCR-pMHC binding kinetics in a physiological context. Second, we introduce a mechanistic framework for interpreting these data, showing that the widely used reversible ligand-receptor model is insufficient in the general case and proposing the TCR cycle model as a minimal systems-level description. Third, we describe a strategy for generating multiplexed, high-throughput datasets and integrating mechanistic modeling with machine learning. Together, this work establishes a foundation for a mechanistically grounded and scalable approach to TCR specificity prediction.

Indexed as

Receptors, Antigen, T-CellHumansKineticsProtein BindingT-LymphocytesReceptors, Antigen, T-Cell

Identifiers

PMID42463643
PMCPMC13376521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.